Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,234 total articles
Power Solutions International (PSIX) has recovered sharply from its late-July lows after Q2 developments and sits at a valuation that looks reasonable relative to its cash generation and profitability. The balance sheet and free cash flow profile give a buffer, while elevated short interest and ongoing legal scrutiny argue for a defined risk plan. …
Novo Nordisk is trading at a valuation that looks unusually cheap for a global leader in diabetes and obesity care. Recent legal wins, a raised full-year outlook and a still-healthy cash-generating core argue for a tactical long. This trade idea gives an entry, stop and target with horizon and risk framing.
Sanofi's fundamentals and pipeline momentum make it resilient to headline risk from vaccine-policy debate. Recent results show broad-based growth and an upgraded 2026 outlook; the trade idea is a mid-term long with an entry at $45.40, a stop at $43.00 and a target at $52.00 (45 trading days).
AVITA's RECELL platform is showing real-world evidence of shorter hospital stays and better healing that should appeal to payers. With a market cap near $300M and recent momentum, a measured long trade targets a re-rate as reimbursement improves. Key risks include legacy reimbursement backlogs, weak liquidity and elevated short interest.
Prenetics has converted early R&D and genomics credibility into a direct-to-consumer consumer health engine with IM8. A $1 billion growth financing led by General Catalyst's CVF, a $70 million cash injection from the Insighta sale, zero debt and $171.1 million in adjusted liquidity create a rare combination: aggressive marketing capacity with a cle…
Harmony Gold (HMY) is a core gold exposure with a growing copper footprint and attractive cashflow characteristics as gold prices stay elevated. At $23.54 and a $14.8B market cap, the stock shows bullish technicals and improving liquidity. Reaffirm Buy with a clear entry at $23.54, stop at $19.00 and primary target at $29.00, horizon mid-term (45 t…
Royal Gold has leaned into growth while keeping leverage minimal. At $261 today, the company offers diversified exposure to gold, silver and copper without mine-level execution risk. With a market cap near $22B, low debt, steady EPS, and dividend growth, RGLD is a tactical long for investors who want leverage to metals with an income kicker and dow…
Generac (GNRC) has shifted from a cyclical residential story toward commercial and industrial and data-center power solutions. Recent results and a large hyperscaler supply deal have reignited revenue growth and earnings beats. Valuation is not cheap, but improving fundamentals and supportive technicals set up a mid-term swing trade with defined ri…
Deutsche Post DHL (ticker DPDGY) has shifted from a legacy postal utility to a higher-quality logistics platform. Operational improvements, disciplined pricing in parcel markets, and network investments justify paying up relative to the old business. This trade targets a near-term entry and a multi-horizon upside while balancing execution and macro…
Halozyme is no longer a small-platform play. With guidance pointing to $1.71-$1.81B in 2026 revenue, royalty streams topping $1B, robust free cash flow, and an opportunistic $300M acquisition, the company looks positioned to compound value into 2027. Technicals are hot, so the trade recommends a disciplined long entry with a clear stop and a pragma…
Sika manufactures specialty chemicals and systems that increase the effective materials content per construction project. With steady end-market fundamentals, price and mix levers, and a track record of share gains, Sika sets up as a compounder inside a construction cycle. This trade idea outlines an actionable long entry, stop, and target, framed …
Walmart plunged after a weak comp-sales print on 08/20/2026, but a deeper look at valuation and margin pressure argues the sell-off did not fully correct for slowing growth. This trade idea recommends a tactical short with a mid-term horizon, precise entry, stop and target, and clear risk controls.
Bloom Energy's factory-built solid oxide fuel cells have become a preferred quick-deploy power source for AI-heavy data centers. With Q2 revenue topping $1.065 billion and a $20 billion backlog, the company is converting scale and product innovation into revenue growth. The stock is richly valued, but the recent pullback and the rollout of Power Co…
EXOR (EXXRF) is trading near key technical support after a measured pullback. For investors who want concentrated Ferrari exposure plus optional upside from EXOR’s real-estate and holding-company optionality, a long trade at $82.60 offers asymmetric reward: limited downside with a clear stop and a multi-month horizon to realize a re-rating or value…
Spectrum Brands combines predictable cash generation with modest leverage and a diversified consumer-products portfolio. At ~$86.82 the stock is trading below recent 52-week highs while still offering an attractive free cash flow yield and a 2.16% dividend - a setup worth trading toward consensus analyst targets near $103 over the next 45 trading d…
Ondas has moved from obscure drone upstart to a mid‑cap defense supplier with heavy order flow, a high‑growth revenue target for 2026 and an M&A push to add recurring software revenue. That combination makes ONDS a high‑volatility, high‑reward trade. We present a tactical long with strict stops and multi-horizon targets tied to contract execution a…
PTC Therapeutics looks attractively positioned for an acquisition premium. Strong Sephience uptake, upgraded product revenue guidance and a materially-sized market cap relative to enterprise value create a scenario where a strategic buyer could unlock multiple expansion. This trade idea lays out an actionable long trade with entry, stop and target,…
Ondas is executing into a hot defense and industrial-autonomy market: big order flow, a $95M+ backlog via Cyberhawk and a raised 2026 revenue target north of $390M. That said, the stock trades like it already bakes in flawless execution - EV/Sales and P/S multiples are extreme, free cash flow is negative, and short interest remains very high. I pre…
Uber trades at roughly $79 with a market cap near $161B and a P/E around 17. The business is cash-generative (free cash flow ~$9.44B) with improving margins and multiple growth levers — mobility rebound, Delivery expansion, Freight scale, and robotaxi optionality via Rivian. The market is pricing a conservative growth profile; we argue growth is wo…
Uranium Energy (UEC) is a volatile, high-upside play on the nuclear restart. The company carries growth optionality — operational ramp at Burke Hollow, projected high revenue CAGR and ample liquidity — against a stretched valuation and recent earnings misses. This trade idea proposes a swing-long entry at $12.75 with a $9.75 stop and a $18.50 targe…
Zoom trades at a reasonable multiple with strong free cash flow and a $1.27B Anthropic stake that could act as a surprise catalyst around Q2 results or follow-on Anthropic news. Technicals are constructive and short interest is light — this is a tactical long for traders willing to hold through one quarterly report.
CVS is a vertically integrated healthcare operator trading below historical peaks with solid free cash flow, a healthy dividend, and multiple operational catalysts. A patient, long-term trade with a defined entry at $93.015, stop at $83, and target of $115 aims to capture a re-rating and continued margin recovery.
Unilever (UL) offers a compelling buy for investors seeking low-volatility exposure to secular emerging-market consumption. At $64.15, the stock yields roughly 3.6%, trades at a 21.4x P/E, and sits on a $138.2B market cap. The company's wide-moat brands across Beauty & Wellbeing, Personal Care and Home Care generate predictable cash flows and provi…
Micron is trading near $967 after a sharp run and intra-day chop. Fundamentals and technicals still favor upside: strong cash flow, minimal leverage, and sustained AI/HBM-driven demand. This is a structured swing trade to capture further upside while protecting against the memory-cycle volatility.
We upgrade Aebi Schmidt to Buy. The company is showing early signs of margin recovery, aftermarket growth and better order visibility that together point to upside versus the current share price. This is a mid-term swing trade with defined entry, stop and target levels and a clear checklist of catalysts and risks to track.
